Salute e Benessere

OMass Therapeutics appoints Birgitte Volck as Non-Executive Director

OMass Therapeutics appoints Birgitte Volck as Non-Executive DirectorOxford, United Kingdom – 26 February 2025 –OMass Therapeutics ('OMass' or 'the Company'), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces that Birgitte Volck MD, PhD has joined its Board as a non-executive director.Dr Volck has over 25 years of industry experience spanning R&D leadership, platform...
Nasdaq GlobeNewswire
26/02/2025

ResMed's Fifth Annual Global Sleep Survey Reveals a World Struggling with Poor…

New insights from 30,026 people across 13 markets show the global scale of poor sleep and its impact on health, work, and relationships 7 out of 10 employed respondents have called in sick at least once in their career due to poor sleep.18% of couples reported sleeping in separate rooms due to snoring and restlessness.Women report fewer quality sleep nights and more difficulties falling asleep than men. SAN DIEGO, Feb.26, 2025(GLOBE NEWSWIRE) --ResMed(NYSE: RMD, ASX:...
Nasdaq GlobeNewswire
26/02/2025

Bracco and Zereau Join Forces for Innovative Research Program Aimed at Improving…

This new stage of the research program, entitled "The Water Project," focuses on the development and testing of scalable, robust urine collection and filtration devices with the goal of integrating a sustainable solution into hospital radiology departments. Patients receiving contrast media in hospitals and diagnostic facilities will use special toilets designed to collect and filter the contrast from their urine. Once saturated, these filters will be collected and processed by…
PR Newswire
26/02/2025

Global Sourcing Fair Vietnam 2025 - More Suppliers, More Opportunities, More…

With access to over 30,000 export-ready products, buyers can connect with OEM, ODM, and OBM manufacturers, discover the latest innovations, and build lasting partnerships with suppliers offering competitive pricing and flexible production capabilities. With access to over30,000 export-ready products, buyers can connect withOEM, ODM, and OBM manufacturers, discover the latest innovations, and build lasting partnerships with suppliers offeringcompetitive pricing and flexible production…
PR Newswire
26/02/2025

12M 2024: Novonesis delivers strong full-year results and expects continued…

Novonesis delivers 8% organic sales growth with an adjusted EBITDA margin of 36.1% in 2024. For 2025, Novonesis presents an outlook of 5-8% organic sales growth with an adjusted EBITDA margin of 37-38%. COPENHAGEN, Denmark – February 26, 2025.In the 2024 financial year, Novonesis delivers 8% organic sales growth with an adjusted EBITDA margin at 36.1%. The sales growth is driven by both Food & Health Biosolutions and Planetary Health Biosolutions. Volumes have increased by ~6% with...
Nasdaq GlobeNewswire
26/02/2025

12M 2024 Company announcement

2024 organic pro forma sales growth of 8%, with pro forma adjusted EBITDA margin of 36.1%.2025 outlook of 5-8% organic pro forma sales growth and 37-38% adjusted EBITDA margin. 2024 organic pro forma sales growth of 8% (Q4: 7%) and 8% on IFRS reported basis (Q4 7%). Food & Health Biosolutions at 7%,and Planetary Health Biosolutions at 9%.2024 pro forma adjusted EBITDA margin of 36.1% (2H 36.8%), with 35.2% for Food & Health Biosolutions and 36.8% for Planetary Health...
Nasdaq GlobeNewswire
26/02/2025

Idorsia reaches an agreement with significant bondholders to restructure its…

Ad hoc announcement pursuant to Art. 53 LR More than the required two-thirds majority of bondholders reach agreement on the main terms for the restructuring of Idorsia's outstanding convertible bond debt – allowing the removal of a large debt overhang and providing CHF 150 million of new fundingAgreement with Viatris to revise collaboration for selatogrel and cenerimod results in the removal of significant cash requirement for 2025Release from exclusivity constraint allows Idorsia to...
Nasdaq GlobeNewswire
26/02/2025

Idorsia and Viatris update their collaboration for selatogrel and cenerimod

Ad hoc announcement pursuant to Art. 53 LR Idorsia's contribution to the development costs reduced by USD 100 millionViatris potential regulatory and sales milestones payments to Idorsia reduced by USD 250 millionAllschwil, Switzerland – February 26, 2025Idorsia Ltd (SIX: IDIA) today announced that it has reached an agreement with Viatris Inc. (NASDAQ: VTRS) to update the terms of the global development and commercialization collaboration for selatogrel and cenerimod. In exchange for...
Nasdaq GlobeNewswire
26/02/2025

Idorsia is released from exclusivity constraint regarding the global rights to…

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – February 26, 2025Idorsia Ltd (SIX: IDIA) today announced that the exclusivity agreement signed in November 2024 with an undisclosed party for the global rights to aprocitentan has concluded without the party signing the deal as foreseen in the non-binding term sheet. Idorsia will retain the exclusivity fee of USD 35 million paid in December 2024. André C. Muller, CEO of Idorsia, commented:“It is disappointing that the...
Nasdaq GlobeNewswire
26/02/2025

Global Advanced Therapy Medicinal Products Market to Grow Immensely at a CAGR of…

Key Takeaways from the Advanced Therapy Medicinal Products Market Report Key Takeaways from the Advanced Therapy Medicinal Products Market Report To read more about the latest highlights related to the advanced therapy medicinal products market, get a snapshot of the key highlights entailed in theGlobal Advanced Therapy Medicinal Products Market Report Advanced Therapy Medicinal Products Overview Advanced Therapy Medicinal Products (ATMPs) represent a cutting-edge category...
PR Newswire
25/02/2025

Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial…

"2024 was another strong year as our proven team delivered significant top- and bottom-line growth along with record total revenues of over $4 billion. Our diversified portfolio spanning sleep1, epilepsy and oncology, with each annualizing at over $1 billion, continued to drive growth," said Bruce Cozadd, chairman and chief executive officer, Jazz Pharmaceuticals. "We are pleased with the continued progress of our late-stage pipeline assets, including the recent launch of Ziihera…
PR Newswire
25/02/2025

DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress

DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the company will participate in the American Academy of Allergy, Asthma, and Immunology and World Allergy Organization (AAAAI/WAO) Joint Congress, February 28-March 3, 2025, in San Diego, CA. An oral abstract presentation by Dr. David Fleischer, FAAAAI, FACAAI, Professor of...
Nasdaq GlobeNewswire
25/02/2025

Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application…

UZEDY is currently approved in the US as a subcutaneous long-acting injectable (LAI) for use every one or two months for the treatment of schizophrenia in adults 1 LAI treatment options may help address unmet needs of people living with bipolar I disorder (BP-I)BP-I filing acceptance for UZEDY represents Teva's commitment to pursuing new advances in neuroscience PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Feb.25, 2025(GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S...
Nasdaq GlobeNewswire
25/02/2025

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; February 25, 2025 –Genmab A/S(Nasdaq: GMAB) will increase its share capital by 10,058 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:709 shares at DKK 962.00, 3,729 shares at DKK 1,025.00, 415 shares at DKK 1,050.00, 200 shares at...
Nasdaq GlobeNewswire
25/02/2025

Bondholders approve amended terms of the 2025 convertible bonds

Ad hoc announcement pursuant to Art. 53 LR The proposed amendments to the terms of the 2025 convertible bond have been approved by the bondholders and will become binding and effective upon approval by the higher cantonal composition authority.Allschwil, Switzerland – February 25, 2025Idorsia Ltd. (SIX: IDIA) today announced the positive outcome of a bondholders' meeting held at 17:30 CET on February 25, 2025. The bondholders' meeting for holders of Idorsia's outstanding 2025...
Nasdaq GlobeNewswire
25/02/2025

Hundreds of tissue regeneration medical devices seized for alleged patent…

These devices lacked essential medical certifications, representing a risk to public health and patient safety. This may result in adverse effects, allergic reactions and rejection of the treated tissues, among other possible health effects. These devices lacked essential medical certifications, representing a risk to public health and patient safety. This may result in adverse effects, allergic reactions and rejection of the treated tissues, among other possible health effects. The main...
PR Newswire
25/02/2025

IBA and Jabil sign contract to install a Be-Wide X-ray solution in Mississippi…

Louvain-la-Neuve, Belgium, February 25, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and electron beam and X-ray solutions for industrial irradiation, and Jabil Inc. a global leader in engineering, manufacturing, and supply chain solutions, announced today they have signed a contract for the installation of a Be-Wide X-ray solution in a greenfield site in Byhalia, Mississippi, USA, to expand Jabil's sterilization capabilities...
Nasdaq GlobeNewswire
25/02/2025

Mobile Cleanroom Market Set to Reach US$ 8.36 Billion by 2031, Driven by Growing…

Download Sample Report- https://www.theinsightpartners.com/sample/TIPRE00039369/ Download Sample Report-https://www.theinsightpartners.com/sample/TIPRE00039369/ Mobile Cleanrooms Market Overview of Report Findings For Detailed Mobile Cleanrooms Market Insights, Visit: https://www.theinsightpartners.com/reports/mobile-cleanroom-market/ Competitive Strategy and Development Global Headlines on Mobile Cleanroom Market Stay Updated on The Latest Mobile...
PR Newswire
25/02/2025

Organoid Services Market Size Projected to Reach US$15.01 Billion by 2031…

The global organoid services market share is projected to grow from US$3.03 billion in 2023 to US$15.01 billion by 2031, driven by the increasing demand for personalized medicine and innovative drug screening services. The global organoid services market share is projected to grow fromUS$3.03 billionin 2023 toUS$15.01 billionby 2031, driven by the increasing demand for personalized medicine and innovative drug screening services. According to a comprehensive report from The Insight...
PR Newswire
25/02/2025

Aquatic Veterinary Market Size Worth $1.93 billion Globally, by 2031 Growing at…

The report provides a data-driven analysis, combining both qualitative and quantitative insights to highlight current market trends and future projections. It also offers actionable information, helping companies develop strategies to drive growth and expand in North America, Europe, or Asia-Pacific. With a global perspective, the research enables businesses to understand diverse healthcare market demands and stay ahead of the competition. A sample of the report is available for preview…
PR Newswire
25/02/2025

Brain Health Supplements Market Size to Reach a Valuation of US$ 20.01 Billion…

The brain health supplements market report comprises a detailed analysis of various dosage forms of brain health supplements and their potential use in improving sleep and recovery, promoting anti-aging and longevity, as well as gaining attention and focus, which are expected to drive market growth in the coming years. The report runs an in-depth analysis of market trends, key players, and future opportunities. The brain health supplements market report comprises a detailed analysis of…
PR Newswire
25/02/2025

Nature's Best Reveal the Hidden Heart Benefits of Omega-3

Results showed that regular consumption of Omega-3 fish oil supplements was associated with a 15% lower risk of progressing from atrial fibrillation to a heart attack. Results showed that regular consumption of Omega-3 fish oil supplements was associated with a 15% lower risk of progressing from atrial fibrillation to a heart attack. Additionally, regular Omega-3 supplementation was further associated with a 9% lower risk of death in individuals with heart failure. Further guidance from...
PR Newswire
25/02/2025

Endoscopic Ultrasonography (EUS) Market to Hit USD 1.93 Billion by 2029 with…

Browse in-depth TOC on "Endoscopic Ultrasonography (EUS) Market" Browse in-depth TOC on "Endoscopic Ultrasonography (EUS) Market" 343 - Tables 64 - Figures 309 - Pages Based on product,the endoscopic ultrasonography market is divided into endoscopes, ultrasound processors, ultrasound probes, ultrasound needles, and accessories. As of 2023, the endoscopes segment accounted for the largest share in the global endoscopic ultrasonography market. The market share can be...
PR Newswire
25/02/2025

MediBeacon® Transdermal GFR System receives device approval in China

In 2021, the NMPA granted the TGFR Innovative Medical Device Designation. Only 10% of applications are granted this designation. Benefits of this registration route including early product promotion are considerable. In 2021, the NMPA granted the TGFR Innovative Medical Device Designation. Only 10% of applications are granted this designation. Benefits of this registration route including early product promotion are considerable. In February, the Clinical Kidney Journal published MediBeacon...
PR Newswire
25/02/2025
Altri  Comunicati